RGX 104

Drug Profile

RGX 104

Alternative Names: RGX-104

Latest Information Update: 08 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer Rgenix
  • Class Antineoplastics; Immunotherapies; Small molecules
  • Mechanism of Action Liver X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Glioblastoma; Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 01 Jun 2018 Efficacy, adverse events, immunogenicity, pharmacodynamics and pharmacokinetics data from a phase Ia/b trial in Solid tumours and Lymphoma presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 29 Oct 2017 Interim pharmacokinetics, pharmacodynamics, efficacy and adverse events data from a phase I trial in solid tumours and lymphoma presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)
  • 29 Oct 2017 Preliminary immunogenicity data from a phase Ia/b trial in solid tumours and lymphoma released by Rgenix
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top